β1-blockers in the reduction of bleeding risk in patients prescribed with potent dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention

被引：0

作者：

Zhang, Shizhao ^{[1
,2
]}

Wu, Yangxun ^{[1
,2
]}

Lv, Chao ^{[1
,2
]}

Liu, Haiping ^{[1
,2
]}

Wang, Yuyan ^{[1
,2
]}

Dong, Lisha ^{[1
,2
]}

Liu, Yuqi ^{[1
,2
]}

Wang, Shengshu ^{[1
,2
]}

Jia, Jianjun ^{[1
,2
]}

Yin, Tong ^{[1
,2
]}

机构：

[1] Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Med Ctr 2, Beijing Key Lab Aging & Geriatr,Inst Geriatr, 28 Fu Xing Rd, Beijing 100853, Peoples R China

[2] Chinese Peoples Liberat Army Gen Hosp, Med Sch Chinese PLA, Beijing, Peoples R China

来源：

HELLENIC JOURNAL OF CARDIOLOGY | 2024年 / 79卷

关键词：

beta; 1-blockers; ticagrelor; bleeding; acute coronary syndrome; percutaneous coronary intervention; ACUTE MYOCARDIAL-INFARCTION; STENT IMPLANTATION; ASSOCIATION; CIRRHOSIS; CLOPIDOGREL; TICAGRELOR; MANAGEMENT; EVENTS; PREDICTORS; MORTALITY;

D O I：

10.1016/j.hjc.2023.09.017

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUND (31-blockers could improve clinical outcomes in patients with coronary artery disease by lowering the heart rate, blood pressure, and myocardial contractility. Moreover, recent studies have suggested that (31-blockers may also have the potential to reduce bleeding risk. OBJECTIVES This study aimed to evaluate the association between (31-blockers and bleeding risk in the patients prescribed with potent dual antiplatelet therapy (DAPT) after acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI). METHODS Patients with ACS or undergoing PCI treated by DAPT of ticagrelor and aspirin were consecutively recruited. Follow-up for all eligible patients was conducted for 1 year. Major bleeding outcomes were defined as events that were type >= 2 based on the Bleeding Academic Research Consortium (BARC) criteria. RESULTS A total of 1,113 eligible ticagrelor-treated patients were recruited. During the 1-year follow-up interval, 142 (12.6%) patients experienced BARC >= 2 bleedings including 23 patients (2.1%) suffering BARC >= 3 bleedings, with the most common site of bleeding located in the gastrointestinal tract. (31-blockers treatment was associated with a lower risk of BARC >= 2 bleedings (11.2% vs. 23.3%, adjusted HR: 0.42, 95% CI: 0.28-0.62, P < 0.01). Moreover, metoprolol (11.1% vs. 23.3%, adjusted HR: 0.56, 95% CI: 0.37-0.83, P < 0.01) and bisoprolol (11.3% vs. 23.3%, adjusted HR: 0.56, 95% CI: 0.33-0.96, P 1/4 0.04) had similar effects on the reduction of bleeding risk. CONCLUSION (31-blockers might be beneficial for the reduction of bleeding risk in potent dual antiplatelet therapy patients with ACS or undergoing PCI. (Hellenic Journal of Cardiology 2024;79:15-24) (c) 2023 Hellenic Society of Cardiology. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

引用

页码：15 / 24

页数：10

共 36 条

[1]

[Anonymous], 2021, Eur Heart J, V42, P1908, DOI 10.1093/eurheartj/ehaa895

[2] Intracranial hemorrhage rates and effect of immediate beta-blocker use in patients with acute myocardial infarction treated with tissue plasminogen activator [J].